Novo Nordisk, the maker of popular weight-loss drugs Ozempic and Wegovy, is partnering with OpenAI to deploy the technology across its operations as it looks to keep pace with rapid expansion in the obesity drug market. The Danish company announced in a statement on Tuesday that it would use AI to analyze complex datasets, identify promising drug candidates…
Novo Nordisk partners with OpenAI in weight loss drug race
Originally reported by The Hill. Read the full story at the original source.
Related Articles
Trump administration ‘confident’ Iran deal will be signed Sunday: Waltz
U.S. Ambassador to the United Nations Mike Waltz said on Sunday that the Trump administration is “confident”...
Reed: Trump’s possible Iran deal a costly ‘birthday gift’
Sen. Jack Reed (D-RI) criticized President Trump over the possible deal to end the war in Iran, describing the plan as a...
NASA’s Artemis III mission is starting to take shape
The Artemis III crew possesses a mix of training and experience that should help to accomplish the mission.
Think a tick bit your dog or cat? Here are symptoms to look for
Tick activity has been high so far this year, with emergency department visits sparked by the pests reaching levels we h...